AstraZeneca issued a press release announcing that clinical trials for their coronavirus vaccine, AZD1222, under development resumed last week in the UK. The vaccine AZD1222 was co-invented by the University of Oxford and its spin-off company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus)…